This therapeutic strategy currently recommended is highly effective favouring the reduction of the HIV viral load, the increase of the CD4 T-lymphocyte count, and the decrease of the occurrence of the HIV-related tumours, such as KS. Here, CD4 is linked to Kaposi's sarcoma.